Committees for Via Oncology meet frequently to update pathway platforms and support the growing needs of physicians, according to Kathleen Lokay.
Committees for Via Oncology meet frequently to update pathway platforms and support the growing needs of physicians, according to Kathleen Lokay.
Transcript
How frequently are your pathways platforms updated to reflect the latest research developments in oncology, especially in the context of using diagnostic tests?
Our medical oncology committees actually meet the most frequently of all. Radiation and surgical oncology don’t meet as often because there’s not as much data changing. But the medical oncology committees meet every quarter. There’s just that much going on in oncology. Then if there is something groundbreaking in between a meeting the committees can always call an ad hoc meeting. So we really want to make sure that we’re addressing new data frequently and that we really keep the pathways up to speed and that new data includes diagnostic tests. So we will be incorporating new biomarkers in virtually every meeting as new data comes out.
Is there anything Via Oncology is thinking about doing next that physicians are looking for?
The thing that we don’t have so much now is precision medicine in the sense of things that are not really standardized care. So if it’s not standardized care, we historical don’t put it in the pathways but we’re increasingly getting our practices asking us to help them with those places where they’re doing genomic sequencing and wanting support for that and wanting to then have their results then be matched with their clinical trials. So it’s stepping outside of what has historically been a more standardized healthcare pathway into something more researched but something that is clearly becoming a bigger and bigger part of practice.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More